Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion

Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion

Background. Despite the dose-dependent response rate of sarcomas to doxorubicin, clinicians limit its cumulative dose due to cardiotoxicity. This study evaluates early evidence of cardiotoxicity in patients treated with high-dose doxorubicin given as a continuous infusion. Methods. Data was collecte...

Full description

Bibliographic Details
Main Authors: Raymundo A. Quintana, Jose Banchs, Ridhi Gupta, Heather Y. Lin, Sean D. Raj, Anthony Conley, Vinod Ravi, Dejka Araujo, Robert S. Benjamin, Shreyaskumar Patel, Saroj Vadhan-Raj, Neeta Somaiah
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Sarcoma
Online Access:http://dx.doi.org/10.1155/2017/7495914

Internet

http://dx.doi.org/10.1155/2017/7495914

Similar Items